- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 29, 2024Robins Kaplan Mourns Death of New York Associate Waleed Abbasi
-
April 29, 2024Robins Kaplan Secures $7.75 Million Verdict in Aerosol Dust Remover Abuse Case
-
April 23, 2024David Martinez Recognized Among Top 100 Lawyers in Los Angeles by LA Business Journal
-
May 9, 2024Property Insurance Claims Group 2024 Conference
-
May 20, 2024The Present and Future of DEI
-
May 23, 202414th Annual Disability Justice Seminar
-
April 30, 2024A World Without Non-Competes: Protecting Confidential Information and Trade Secrets Following the FTC's Ban
-
First QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin
-
March 2024e-Commerce: Pitfalls and Protections
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Endo Ventures Unlimited Co. v. Nexus Pharms. Inc.
ephedrine sulfate
March 25, 2024
Case Name: Endo Ventures Unlimited Co. v. Nexus Pharms. Inc., Civ. No. 23-cv-299-BHL, 2024 WL 1254358 (E.D. Wis. Mar. 25, 2024) (Ludwig, J.)
Drug Product and Patent(s)-in-Suit: ephedrine sulfate; U.S. Patents Nos. 10,869,845 (“the ’845 patent”) and 11,491,121 (“the ’121 patent”)
Nature of the Case and Issue(s) Presented: Endo sued Nexus in the Eastern District of Wisconsin, alleging infringement of the patents-in-suit, after Nexus filed a supplement to its NDA seeking approval to market ephedrine sulfate injections in pre-filled syringes (the parties had settled a previous suit on Nexus’s initial NDA).
Nexus had built a manufacturing facility in Pleasant Prairie, Wisconsin, and it planned to market and sell the accused product in Wisconsin. But as of the date of Endo’s complaint, Nexus had not manufactured any drug products for commercial distribution in that facility. It had not derived revenue from operations at that site. And it had not stored product in its warehouse in the district. Thus, Nexus moved to dismiss for lack of personal jurisdiction. The court granted the motion.
Why Nexus Prevailed: The court granted Nexus’s Rule 12(b)(2) motion because it could not exercise personal jurisdiction (general or specific) over Nexus. Nexus’s principal place of business and state of incorporation were in Illinois, not Wisconsin. And Nexus’s investments in a Wisconsin-based facility were insufficient to establish general jurisdiction, in part because the facts did not show that Nexus used Wisconsin as its primary manufacturing location. The court could not find that Nexus was “at home” in Wisconsin.
The court also declined to exercise specific personal jurisdiction over Nexus. Endo relied on Nexus’s intentions for its Wisconsin facility—a fatal flaw in Endo’s arguments. Actions after Endo initiated suit are not relevant to the personal jurisdiction analysis. And as of the date of the complaint, Nexus’s plans for the Wisconsin facility had yet to come to fruition.
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.